Progut (Esomeprazole): A Proton Pump Inhibitor (PPI) for Acid-Related Conditions

Progut contains Esomeprazole, a proton pump inhibitor (PPI) that effectively suppresses gastric acid secretion. It is indicated for a range of acid-related gastrointestinal conditions, from chronic heartburn to the healing and maintenance of erosive esophagitis, and as part of combination therapy for Helicobacter pylori infection.

How Progut Works (Pharmacology)

Esomeprazole works by specifically inhibiting the H+/K+-ATPase (proton pump) in the gastric parietal cells of the stomach. This enzyme is responsible for the final step in acid production. By inhibiting this pump, Esomeprazole significantly reduces the amount of gastric acid secreted into the stomach.

Esomeprazole is the S-isomer of omeprazole, making it the first single optical isomer PPI. This specific isomer provides better acid control compared to racemic (mixture of S- and R-isomers) proton pump inhibitors.

Pharmacokinetics:

• Absorption: Progut capsules contain an enteric-coated pellet formulation, designed to protect the active ingredient from stomach acid. After oral administration, peak plasma levels (Cmax) are typically reached in about 1.5 hours (Tmax).
• Dose Proportionality: The Cmax increases proportionally with the dose.

Key Indications & Benefits

Progut is indicated for:

• Relief from chronic heartburn symptoms and other symptoms associated with Gastroesophageal Reflux Disease (GERD).
• Healing of erosive esophagitis (inflammation and damage to the esophagus due to acid reflux).
• Maintenance of healing of erosive esophagitis to prevent recurrence.
• In combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori infection in patients with duodenal ulcer disease.
• Zollinger-Ellison Syndrome (a condition causing excessive stomach acid production).
• Acid-related Dyspepsia (indigestion).
• Duodenal & Gastric ulcer.

Dosage & Administration

Progut is available in oral forms (tablet/capsule, oral suspension) and for IV injection/infusion. Always consult a registered physician for medication use.

Oral Dosage Form (Tablet or Capsule): Should be swallowed whole and taken one hour before a meal.

• Healing of Erosive Esophagitis:
  • 20 mg or 40 mg once daily for 4-8 weeks. An additional 4-8 weeks may be considered if healing is not complete.
• Maintenance of Healing of Erosive Esophagitis:
  • 20 mg once daily (clinical studies did not extend beyond 6 months for this indication).
• Symptomatic GERD:
  • 20 mg once daily for 4 weeks. An additional 4 weeks may be considered if symptoms do not resolve completely.
• Helicobacter Pylori Eradication (Triple Therapy):
  • Esomeprazole 40 mg once daily for 10 days.
  • Amoxicillin 1000 mg twice daily for 10 days.
  • Clarithromycin 500 mg twice daily for 10 days.
• Zollinger-Ellison Syndrome:
  • The dose is 20-80 mg once daily. Dosage should be adjusted individually and continued as long as clinically indicated.
• Acid-related Dyspepsia:
  • 20-40 mg once daily for 2-4 weeks according to response.
• Duodenal Ulcer:
  • 20 mg once daily for 2-4 weeks.
• Gastric Ulcer:
  • 20-40 mg once daily for 4-8 weeks.

Oral Suspension Preparation:

• Pour whole contents of packet into a small glass with 15 mL of water.
• Stir well and let thicken for 2-3 minutes.
• Stir again and drink within 30 minutes.
• If any remains, add more water, stir, and drink immediately.
• For nasogastric or gastric tube administration: Use 15 mL water in syringe, shake, let thicken 2-3 minutes, shake again, and inject within 30 minutes. Flush remaining contents.

IV Injection or IV Infusion:

• GERD with Erosive Esophagitis:
  • Adults ($\ge$18 years): 20 mg or 40 mg once daily.
    • IV Injection: Administer over >3 minutes.
    • IV Infusion: Administer over 10-30 minutes.
  • Pediatric Patients (1 year to 17 years):
    • Body weight < 55 kg: 10 mg once daily.
    • Body weight ≥ 55 kg: 20 mg once daily.
    • IV Infusion: Administer over 10-30 minutes.
  • Pediatric Patients (1 month to <1 year):
    • 0.5 mg/kg once daily.
    • IV Infusion: Administer over 10-30 minutes.
• Risk reduction of rebleeding of Gastric or Duodenal Ulcers following therapeutic endoscopy (Adults $\ge$18 years):
  • 80 mg IV Infusion over 30 minutes, followed by a continuous infusion of 8 mg/h for a total treatment duration of 72 hours.

IV Injection Preparation:

• Add 5 mL of 0.9% Sodium Chloride for intravenous injection to the vial.
• The reconstituted solution should be clear and colorless to very slightly yellow.
• Administer intravenously over at least 3 minutes.
• Use prepared solution within 12 hours and keep at a maximum of 30°C under normal indoor lighting.

Important Considerations & Warnings

It is crucial to discuss your full medical history with your doctor before taking Progut.

Contraindications:

• Patients with known hypersensitivity to Esomeprazole or any of the formulation components.

Side Effects:

• Most frequently occurring adverse events: Headache, diarrhea, nausea, flatulence, abdominal pain, constipation, and dry mouth.
• The types of related adverse events observed during maintenance treatment (up to 12 months) are similar to those seen during short-term treatment.

Pregnancy & Lactation:

• Pregnancy: There are no adequate and well-controlled studies in pregnant women. Animal studies have not shown teratogenic effects. Progut should be used during pregnancy only if clearly needed.
• Lactation: The excretion of Esomeprazole in human milk has not been studied. Therefore, breast-feeding should be discontinued if the use of Esomeprazole is considered essential.

Precautions & Warnings:

• Gastric Malignancy: Symptomatic response to therapy with Progut does not preclude the presence of gastric malignancy.
• Administration:
  • Progut capsules should be taken at least one hour before meals.
  • For patients with swallowing difficulty: Capsules can be opened, and pellets sprinkled onto one tablespoon of applesauce. The mixture should be swallowed immediately without chewing or crushing the pellets. Do not use hot applesauce or store the mixture for future use.
• Antacids: Antacids may be used while taking Progut.

Use in Special Populations:

• Pediatric Use: Safety and effectiveness in pediatric patients have not been established (except for specific IV indications as mentioned above).
• Geriatric Use: No overall differences in safety and efficacy have been observed between elderly and younger individuals in clinical experience. However, greater sensitivity of some older individuals cannot be ruled out.
• Hepatic Insufficiency: No dosage adjustment is recommended for patients with mild to moderate hepatic insufficiency. However, in patients with severe hepatic insufficiency, a dose of 20 mg once daily should not be exceeded.
• Renal Insufficiency: The pharmacokinetics of Progut are not expected to be significantly altered in patients with renal impairment, as less than 1% of Progut is excreted unchanged in the urine.

Drug Interactions:

Esomeprazole is extensively metabolized in the liver by CYP2C19 and CYP3A4.

• No clinically relevant interactions expected with: CYPs 1A2, 2A6, 2C9, 2D6, 2E1, and 3A4.
• No clinically significant interactions found with: Phenytoin, warfarin, quinidine, clarithromycin, or amoxicillin.
• Potential Interference with CYP2C19: Progut may interfere with CYP2C19, its major metabolizing enzyme.
  • Diazepam: Co-administration of Progut 30 mg and diazepam (a CYP2C19 substrate) resulted in a 45% decrease in diazepam clearance, with increased plasma levels observed 12 hours after dosing and onwards.
• Interference with Drug Absorption (due to reduced gastric pH): Progut inhibits gastric acid secretion, which may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts, and digoxin).
• Oral Contraceptives, Diazepam, Phenytoin, Quinidine: Co-administration of these drugs does not appear to change the pharmacokinetic profile of Progut.
• Triple Therapy with Clarithromycin and Amoxicillin: Co-administration results in increases in the plasma levels of Progut and 14-hydroxyclarithromycin.

Overdose Effects:

• A single oral dose of 510 mg/kg was lethal to rats (about 103 times the human dose). Major signs of acute toxicity were reduced motor activity, changes in respiratory frequency, tremor, ataxia, and intermittent clonic convulsions.
• There have been no reports of overdose with Progut in humans.
• No specific antidote for Progut is known.
• Since Progut is extensively protein-bound, it is not expected to be removed by dialysis.
• In the event of overdosage, treatment should be symptomatic and supportive. The possibility of multiple drug ingestion should also be considered.

Storage Conditions

Store at a temperature not exceeding 30°C in a dry place. Protect from light and moisture. Keep out of reach of children.